Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Searches For CEO, Appoints Flavell To Board

Premium

NEW HAVEN, Conn.--Jonathan Rothberg, chairman of the board of CuraGen, said he has begun a search for a president and chief executive officer for the company. "CuraGen has been experiencing tremendous growth through its recent collaborations, technological advancements, and scientific progress," Rothberg said. "Given our increasing momentum in the marketplace, I desire a partner at the helm of the company to complement my scientific skills as a leader of a large and rapidly growing business," he added. In the past year, the 300-person company, which was founded by Rothberg in 1993, has discovered more than 60,000 human genetic variations; signed a pharmacogenomics deal with Glaxo Wellcome; issued a patent on its GeneCalling technology; and announced a comprehensive product discovery and development collaboration with Hoffmann-La Roche.

CuraGen also recently appointed Richard Flavell, chairman and professor of immunobiology at Yale University, to its scientific advisory board. Flavell is also an investigator at Howard Hughes Medical Institute.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.